Brief: Jade Biosciences - Enters Exclusive Worldwide License Agreement With Paragon Therapeutics - SEC Filing
01/07/2026 22:34
BRIEF-Jade Biosciences - Enters Exclusive Worldwide License Agreement With Paragon Therapeutics - SEC Filing July 1 (Reuters) - Jade Biosciences Inc JBIO.O:
JADE BIOSCIENCES - ENTERS EXCLUSIVE WORLDWIDE LICENSE AGREEMENT WITH PARAGON THERAPEUTICS - SEC FILING
JADE BIOSCIENCES - TO PAY UP TO $22 MILLION IN MILESTONE PAYMENTS TO PARAGON - SEC FILING
JADE BIOSCIENCES - TO PAY PARAGON LOW TO MID-SINGLE-DIGIT PERCENTAGE ROYALTIES ON NET SALES OF LICENSED PRODUCTS - SEC FILING
JADE BIOSCIENCES - PARAGON BARRED FROM NEW CAMPAIGNS TARGETING LICENSED TARGET FOR AT LEAST FIVE YEARS - SEC FILING
Source text: [ID:n0001193125-26-292704]
Further company coverage: JBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jade Biosciences
See all newsBrief: Jade Biosciences Announces Preclinical Data Characterizing Jade301, A Potentially Best-In-Class, Half-Life-Extended Anti-Ifn-Β Monoclonal Antibody In Development For Dermatomyositis, At Eadv 2026
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Jade Biosciences Inc reports results for the quarter ended June 30 - Earnings Summary
Jade Biosciences Q2 net loss widens as costs rise
Brief: Jade Biosciences, Inc Q2 Cash & Investments USD 461.2 Million